---

SOLITARY NODULE OF THYROID

(50 Marks - RGUHS Format)

---

DEFINITION

• Cummings Otolaryngology, 7e, p. 2375
• Scott-Brown's Otorhinolaryngology H&N Surgery, Vol 1, p. 761

---

INCIDENCE & PREVALENCE

• Present in approximately 4% of the general population by palpation
• On ultrasonography: 10% of 25-year-olds and 55% of women over 70 have nodules
• Annual incidence: ~0.1% (approximately 300,000 new nodules/year in the USA)
• Only 5% of all thyroid nodules are malignant (approximately 1 in 20 new nodules contains carcinoma)
• The challenge: identify the malignant minority from the benign majority

• Cummings Otolaryngology, 7e, p. 2375
• Scott-Brown's Vol 1, p. 761

---

ETIOLOGY / CAUSES OF STN

---

CLINICAL PRESENTATION

A. History

• Most patients are asymptomatic - nodule discovered incidentally on self-examination or imaging
• Neck swelling - duration, rate of growth, change in size
• Rapid growth suggests hemorrhage into a cyst OR malignancy
• Pain - rarely associated with carcinoma; more common with hemorrhage into a benign nodule
• Sudden painful enlargement - hemorrhage into a cyst

• Hoarseness / voice change - suggests recurrent laryngeal nerve (RLN) involvement (vocal cord paralysis may be present WITHOUT voice change)
• Dysphagia - esophageal compression or invasion
• Dyspnea / stridor - tracheal compression or invasion
• Sensation of a lump in the throat

• Most patients are euthyroid at presentation
• Symptoms of hyperthyroidism: palpitations, heat intolerance, tremor, weight loss (toxic nodule)
• Symptoms of hypothyroidism: cold intolerance, weight gain, constipation (Hashimoto's)

• Schwartz's Principles of Surgery, 11e, p. 1669
• Cummings Otolaryngology, 7e, p. 2375

B. Physical Examination

• Signs of hypo/hyperthyroidism
• Pemberton's sign (positive in retrosternal extension): facial flushing and cervical vein dilatation on raising arms above head

• Palpate cervical chain - cervical lymphadenopathy strongly suggests malignancy
• Mediastinal nodes may be present

• Assess vocal cord mobility - paralysis indicates RLN involvement
• This is mandatory before any thyroid surgery

---

DIAGRAM: ANATOMY OF THE THYROID GLAND

                    Hyoid bone
                        |
                    Thyroid cartilage
                        |
              ┌─────────┴─────────┐
         Rt. Lobe              Lt. Lobe
         (with nodule)         
              └────┬────────────┘
                   │
            Isthmus (crosses 2nd-4th tracheal rings)
                   |
            Pyramidal lobe (if present)
                   |
                Trachea

Relations:
- Anterior: strap muscles, SCM, platysma
- Posterior: RLN, parathyroid glands, carotid sheath
- Blood supply: Superior thyroid artery (ECA), Inferior thyroid artery (thyrocervical trunk)

---

INVESTIGATIONS

1. Laboratory Tests

"TSH measurement serves as an excellent screening test...full thyroid function tests can be performed if the TSH level is abnormal." - Cummings, p. 2375

2. Imaging

A. Ultrasonography (First-line Imaging)

• Most cost-effective investigation for structural information
• Determines: number, size, echogenicity, vascularity, calcifications, margin regularity
• Should be performed in ALL patients with a palpable thyroid nodule

Scott-Brown's Vol 1, Box 60.6, p. 761

---

Goldman-Cecil Medicine, 2e; 2023 ETA Guidelines (PMID: 37358008)

B. Radionuclide Scanning (Thyroid Scintigraphy)

• Uses: ¹²³I or ⁹⁹ᵐTc pertechnetate
• Hot nodule (hyperfunctioning): concentrated uptake, very low malignancy risk (<1%)
• Cold nodule (hypofunctioning): absent uptake, malignancy risk 15-20%
• Warm nodule: equal uptake as surrounding gland, low malignancy risk

1. Suppressed TSH (to differentiate toxic nodule from Graves' + cold nodule)
2. After indeterminate FNAC (to assess functionality)
3. NOT required as routine first-line investigation in euthyroid patients

"With the evolution of FNAC, radionuclide scanning is not routinely performed in the evaluation of a thyroid nodule." - Cummings, p. 2376

C. CT / MRI

• NOT first-line; ancillary to ultrasound
• Indications: large goiters with substernal extension, tracheal compression assessment, pre-operative staging of known malignancy
• Note: IV iodine-contrast CT delays ¹³¹I treatment by weeks - avoid before planned RAI therapy

D. PET-FDG Scan

• Used to localize thyroid cancer recurrence in patients with elevated Tg but negative whole-body scintiscans
• Some utility for staging invasive Hurthle cell carcinoma

3. Fine Needle Aspiration Cytology (FNAC) - The Most Important Investigation

"FNAC has become the procedure of choice in the evaluation of thyroid nodules." - Cummings Otolaryngology, p. 2375

• Minimally invasive, office procedure
• High accuracy (99% for papillary carcinoma, false positive <1%)
• Reduced unnecessary surgery by 35-75%
• Tripled yield of malignancy in surgical specimens

• 23-25 gauge needle, 10 mL syringe
• With or without ultrasound guidance (US-guided preferred for impalpable/cystic/previously non-diagnostic nodules)
• Multiple passes; smeared on slides; fixed in alcohol or air-dried

2023 Bethesda System Update - Ali SZ et al., Thyroid 2023 (PMID: 37427847)

• Cannot differentiate follicular adenoma from follicular carcinoma (requires histological proof of capsular/vascular invasion)
• 15% aspirates are non-diagnostic

---

DIFFERENTIAL DIAGNOSIS OF STN

1. Dominant nodule in multinodular goiter
2. Thyroid adenoma (follicular)
3. Thyroid cyst (colloid, hemorrhagic)
4. Thyroid carcinoma
5. Hashimoto's thyroiditis (focal)
6. De Quervain's thyroiditis (early)
7. Thyroglossal duct cyst (midline)
8. Parathyroid adenoma/cyst
9. Lymph node (reactive/malignant)
10. Dermoid cyst

---

MANAGEMENT

FLOWCHART 1: Rational Approach to Management of a Thyroid Nodule (Cummings, Fig. 122.9)

---

FLOWCHART 2: Step-by-Step Management Algorithm

PATIENT PRESENTS WITH THYROID NODULE
              ↓
    History + Physical Examination
    (Identify high-risk features)
              ↓
         Serum TSH
    ┌────────┼────────┐
    ↓        ↓        ↓
  LOW      NORMAL    HIGH
  TSH       TSH      TSH
    ↓        ↓        ↓
Radionuclide  FNAC + USS  Treat Hashimoto's /
   Scan                   Hypothyroidism
    ↓                     then FNAC
   ┌─────┐
   ↓     ↓
 HOT   COLD
(toxic) (nodule)
   ↓     ↓
Treat  FNAC +
thyro- Surgery
toxicosis

         FNAC RESULT
    ┌────┬────┬────┬────┬────┐
    ↓    ↓    ↓    ↓    ↓    ↓
  Non-  Benign AUS  FN  Susp. Malig-
 diag.         /    /    for   nant
               FLUS  SFN  Malig
    ↓    ↓    ↓    ↓    ↓    ↓
 Repeat Observe/ Repeat/ Diag. Near-  Total
 USS-  USS  Molecular  Lobect- total  Thyroid-
 guided follow  testing  omy   Thyroid- ectomy
 FNAC   up                   ectomy
              
If Benign but grows → Consider Surgery

---

A. CONSERVATIVE / NON-SURGICAL MANAGEMENT

1. Observation / Surveillance: For Bethesda II (benign) - clinical follow-up and repeat ultrasound at 12-24 months
2. TSH Suppression Therapy (Levothyroxine): Historically used but largely ABANDONED as routine due to:
   • Modest/inconsistent effect on nodule size
   • Side effects (atrial fibrillation, osteoporosis)
   • Not recommended by ATA/ETA 2023 guidelines
3. Thyroid hormone replacement: For associated hypothyroidism

B. SURGICAL MANAGEMENT

1. FNAC: Bethesda V or VI (malignant / suspicious)
2. Bethesda IV (Follicular neoplasm)
3. Symptomatic compressive nodule (dyspnea, dysphagia)
4. Rapidly enlarging nodule
5. Cosmetically unacceptable goiter
6. Toxic nodule (if not suitable for RAI)
7. Retrosternal extension
8. Repeated non-diagnostic FNAC (especially solid nodule in male)
9. High clinical suspicion despite benign FNAC

• Make patient euthyroid (if toxic)
• Indirect laryngoscopy / flexible nasolaryngoscopy - document vocal cord function
• Sestamibi scan if parathyroid involvement suspected
• USG neck for lymph node mapping
• MDT discussion

C. RADIOIODINE (¹³¹I) THERAPY

• Used post-thyroidectomy for:
  1. Remnant ablation after total thyroidectomy for differentiated thyroid cancer
  2. Treatment of functioning metastases
  3. Adjuvant therapy for high/intermediate risk DTC
• Requires TSH stimulation (either thyroid hormone withdrawal or recombinant TSH - Thyrogen)
• Contraindications: pregnancy, breastfeeding

D. EXTERNAL BEAM RADIATION THERAPY (EBRT)

• Anaplastic carcinoma (often combined with chemotherapy)
• Medullary carcinoma with unresectable disease
• Lymphoma (sensitive to radiation and chemotherapy)

E. TARGETED / SYSTEMIC THERAPY (Recent Advances)

• Sorafenib, Lenvatinib: Tyrosine kinase inhibitors for radioiodine-refractory DTC
• Cabozantinib, Vandetanib: For medullary thyroid cancer
• BRAF inhibitors (Dabrafenib + Trametinib): For BRAF V600E-mutated PTC (recent advance)

---

PROGNOSIS STAGING

• Metastasis (distant)
• Age at diagnosis
• Completeness of resection
• Invasoion (extrathyroidal)
• Size

---

MOLECULAR TESTING (Recent Advance)

2023 ETA Clinical Practice Guidelines for Thyroid Nodule Management (PMID: 37358008) Grani G et al., Nat Rev Endocrinol 2024 (PMID: 39152228)

---

MINIMALLY INVASIVE / NOVEL THERAPIES (Recent Advances 2023-2025)

1. Radiofrequency Ablation (RFA): For benign, symptomatic, autonomously functioning nodules; alternative to surgery in non-surgical candidates
2. High-Intensity Focused Ultrasound (HIFU): Non-invasive thermal ablation
3. Ethanol Ablation: For cystic thyroid nodules
4. Laser Ablation: For small solid benign nodules
5. Robotic / remote access thyroidectomy: Trans-axillary, trans-oral (TOETVA) approach - improved cosmesis

Grani G, Sponziello M, Filetti S. Nat Rev Endocrinol 2024 (PMID: 39152228)

---

ACTIVE SURVEILLANCE (Very Small PTC)

• For papillary thyroid microcarcinoma (PTMC) <1 cm, low-risk, older patients, non-aggressive histology: active surveillance (watchful waiting) may be appropriate instead of immediate surgery
• Supported by Japanese Kuma Hospital data: <4% progression rate over 10 years
• 2023 ETA and ATA guidelines support this approach in selected cases
• Repeat USG every 6-12 months; proceed to surgery if growth >3 mm or new LN involvement

---

SPECIAL SITUATIONS

Thyroid Nodule in Pregnancy

• TSH reference range lower in first trimester
• FNAC can be performed safely
• Surgery if malignant: best in 2nd trimester
• RAI is absolutely contraindicated

Post-Radiation Thyroid Nodule

• 40% chance of malignancy
• Requires aggressive workup and low threshold for surgery
• Most are papillary carcinoma; some with RET/PTC translocations more aggressive
• Lifelong monitoring required (Schwartz's 11e, p. 1669)

---

SUMMARY TABLE: BENIGN vs. MALIGNANT FEATURES

---

RECENT ADVANCES SUMMARY (2022-2025)

1. 2023 Bethesda System update (PMID: 37427847) - refined cancer risk estimates per category with implications for molecular testing
2. 2023 ETA Guidelines (PMID: 37358008) - new TI-RADS based risk stratification; active surveillance for low-risk PTMC
3. Molecular testing (ThyroSeq v3, Afirma GSC) - now standard for Bethesda III/IV indeterminate nodules, reduces unnecessary surgery
4. Thermal ablation techniques (RFA, HIFU, laser) - approved alternatives to surgery for benign symptomatic/autonomously functioning nodules
5. BRAF + TERT co-mutation - strongest molecular predictor of aggressive behavior and recurrence in PTC
6. Lenvatinib/Sorafenib - approved for radioiodine-refractory differentiated thyroid cancer; improved progression-free survival
7. Robotic remote-access thyroidectomy (TOETVA) - scarless surgery for cosmetically sensitive patients
8. AI-assisted ultrasound - deep learning algorithms improving accuracy of malignancy prediction on USS

Chen DW et al., Lancet 2023 (PMID: 37023783) Grani G et al., Nat Rev Endocrinol 2024 (PMID: 39152228) 2023 ETA Guidelines (PMID: 37358008)

---

REFERENCES (For RGUHS Answer)

1. Cummings Otolaryngology Head and Neck Surgery, 7th Edition - Chapter 122, pp. 2374-2380
2. Scott-Brown's Otorhinolaryngology Head & Neck Surgery, 8th Edition (Vol. 1) - Chapter 60, pp. 759-762
3. Schwartz's Principles of Surgery, 11th Edition - Chapter 38, pp. 1668-1670
4. Sabiston Textbook of Surgery, 21st Edition - Chapter 36
5. K.J. Lee's Essential Otolaryngology, 11th Edition
6. P.L. Dhingra - Diseases of Ear, Nose and Throat, 7th Edition
7. M. Hazarika - Textbook of Ear, Nose and Throat Diseases (Includes thyroid surgery chapter)
8. Zakir Hussain - Textbook of ENT and H&N Surgery
9. Stell and Maran's Head and Neck Surgery - Thyroid chapter
10. Durante C et al. - 2023 ETA Clinical Practice Guidelines for thyroid nodule management. Eur Thyroid J, 2023. [PMID: 37358008]
11. Ali SZ, Baloch ZW et al. - The 2023 Bethesda System for Reporting Thyroid Cytopathology. Thyroid, 2023. [PMID: 37427847]
12. Grani G, Sponziello M, Filetti S - Thyroid nodules: diagnosis and management. Nat Rev Endocrinol, 2024. [PMID: 39152228]
13. Chen DW et al. - Thyroid cancer. Lancet, 2023. [PMID: 37023783]

---

Note to RGUHS Examinees: This answer covers the complete spectrum expected for a 50-mark long essay. Draw the management algorithm flowchart (Cummings Fig. 122.9), Bethesda classification table, and a simple diagram of the thyroid anatomy/relations. The key examiner "scoring points" are: Definition → Incidence → Etiology → Clinical Presentation (History + PE) → Investigations (Labs + USS + FNAC/Bethesda) → Management Flowchart → Surgical options + Complications → Prognosis → Recent Advances.---

Quick Answer Summary

---

SOLITARY NODULE OF THYROID - 50 Marks (RGUHS)

Textbook Sources Confirmed in Library:

• Cummings Otolaryngology (7e) - Chapter 122, pp. 2374-2380 - extensive management algorithm + FNAC section
• Scott-Brown's ORL H&N Surgery (Vol 1) - Chapter 60, p. 761 - USS features Box 60.6 + ultrasound images
• Schwartz's Principles of Surgery (11e) - STN chapter including radiation risk data
• Sabiston Textbook of Surgery (21e) - Thyroid nodule clinical presentation and workup
• K.J. Lee's Essential Otolaryngology, Dhingra, Hazarika, Zakir Hussain, Stell & Maran - all standard ENT textbook references are cited throughout

---

1. Definition + Incidence - 4% by palpation, 55% by USS in elderly; only 5% malignant
2. Etiology - Benign (colloid, adenoma, cyst, thyroiditis) vs. Malignant (PTC 80%, FTC 10%, MTC, anaplastic)
3. Clinical Presentation - History (risk factors for malignancy, compressive symptoms) + Physical examination (consistency, fixity, LN, laryngoscopy)
4. Investigations - Serum TSH → USS (TI-RADS) → FNAC/Bethesda 2023 → Radionuclide scan → CT/MRI
5. Management Flowchart (from Cummings Fig. 122.9 - included as image above)
6. Surgical Management - Hemithyroidectomy / Near-total / Total thyroidectomy + Complications (RLN injury, hypoparathyroidism)
7. Prognosis - ATA risk stratification (Low/Intermediate/High), MACIS score
8. Recent Advances (2023-2025) - 2023 Bethesda update, 2023 ETA Guidelines, Molecular testing (ThyroSeq v3, Afirma GSC), RFA/HIFU thermal ablation, BRAF+TERT co-mutation, Lenvatinib, TOETVA, AI-assisted USS

• 2023 ETA Guidelines - Durante C et al.
• 2023 Bethesda System - Ali SZ et al.
• Thyroid cancer review - Chen DW et al., Lancet 2023
• Thyroid nodules: diagnosis & management - Grani G et al., Nat Rev Endocrinol 2024